

Intellia Therapeutics is a leading genome editing company focused on developing proprietary, curative therapeutics using the CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course, and through improved cell therapies that can treat cancer and immunological diseases, or can replace patients’ diseased cells. The combination of deep scientific, technical and clinical development experience, along with its leading intellectual property portfolio, puts Intellia in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create a new class of therapeutic products. Among its major competitors, Intellia Therapeutics is ranked in 3rd place for NPS while Spark Therapeutics is 1st, and Caribou Biosciences is 2nd.Their current market cap is $5.42B
Intellia Therapeutics's Net Promoter Score (NPS) is a 49 with 66% Promoters, 17% Passives, and 17% Detractors. Net Promoter Score tracks whether Intellia Therapeutics's customers would recommend using the product based on a scale of -100 to 100.
| 66% | Promoters |
|---|---|
| 17% | Passives |
| 17% | Detractors |
| Summary | Date | Score |
|---|---|---|
Jul 2022 0 | Jul 2022 | 0 |
Nov 2022 50 | Nov 2022 | 50 |
May 2023 66 | May 2023 | 66 |
Jan 2024 75 | Jan 2024 | 75 |
Aug 2024 80 | Aug 2024 | 80 |
Mar 2025 49 | Mar 2025 | 49 |
Intellia Therapeutics is ranked first for NPS among its competitors. Vertex Pharmaceuticals and Illumina come in second and third, with Biogen coming in at #4. Among those competitors, it is the lowest valued company behind Vertex Pharmaceuticals.
![]() Intellia Therapeutics | ![]() Biogen | ![]() Illumina | ![]() Vertex Pharmaceuticals | |
| Global Ranking | #- | #388 | #985 | #- |
| NPS | 49 | 21 | 26 | 34 |
| Social Sentiment Calculated by analyzing social media and other online mentions | - | Neutral | - | Neutral |
| Valuation Updated every 24 hours for public companies | $5.42B | $42.46B | $70.95B | $89.62B |
Net Promoter Score (NPS) is a management tool that can be used to gauge the satisfaction of a firm's customer relationships. NPS has been widely adopted as a key metric often linked to the revenue potential of a company’s product or service. The metric is based on customer responses to the question: "On a scale of 0 to 10, how likely are you to recommend the product to a friend?"
Those who respond with a score of 9 to 10 are known as Promoters, and are widely associated with behaviors that create value, including actively encouraging others to use the product or service. Those who respond with a score of 7 or 8 are categorized as Passives, and they are believed to be less likely to exhibit the value-creation traits of Promoters having a largely neutral effect on other consumers. Detractors are those who fall in the score range of 0 to 6 and represent dissatisfied customers of the product sometimes actively recommending against using the product.
Compared to its competitors, Intellia Therapeutics's NPS is rated right above Vertex Pharmaceuticals, and is preceded by Caribou Biosciences.
Customer Loyalty is a strong indicator of whether or not a customer will choose a brand repeatedly over a competitor that offers similar products/services.
68% of Intellia Therapeutics users/customers answered "Yes" when asked: "Would you consider yourself a loyal user/customer?"
Sign Up to see the full customer demographics data and the people that answered "Yes" when asked "Would you consider yourself a loyal user/customer?"
Compared to its competitors, Intellia Therapeutics's Customer Loyalty score is rated right above bluebird bio, and is preceded by Illumina.
| COMPANY | Customer Loyalty Score | |
|---|---|---|
![]() | Spark Therapeutics | 100% |
![]() | Caribou Biosciences | 100% |
![]() | Agios Pharmaceuticals | 100% |
![]() | Alnylam Pharmaceuticals | 85% |
![]() | Vertex Pharmaceuticals | 76% |
![]() | Biogen | 75% |
![]() | Illumina | 73% |
![]() | Intellia Therapeutics | 68% |
![]() | bluebird bio | 65% |
![]() | Editas Medicine | N/A |
![]() | Rubius Therapeutics | N/A |
Intellia Therapeutics has an overall Product Quality score of 3.5 out of 5 stars rated by its users and customers.
Sign Up to unlock Intellia Therapeutics' overall Product Quality score rated by its users and customers.
Intellia Therapeutics’s product quality score is a 3.5 out of 5 as rated by its users and customers.
Compared to its competitors, Intellia Therapeutics's Product Quality score is rated right above Vertex Pharmaceuticals, and is preceded by Spark Therapeutics.
| COMPANY | Product Quality Score | |
|---|---|---|
![]() | Caribou Biosciences | 5/5 |
![]() | bluebird bio | 4.2/5 |
![]() | Biogen | 4/5 |
![]() | Illumina | 3.9/5 |
![]() | Alnylam Pharmaceuticals | 3.8/5 |
![]() | Spark Therapeutics | 3.7/5 |
![]() | Intellia Therapeutics | 3.5/5 |
![]() | Vertex Pharmaceuticals | 3.5/5 |
![]() | Agios Pharmaceuticals | 1.5/5 |
![]() | Editas Medicine | N/A |
![]() | Rubius Therapeutics | N/A |
Intellia Therapeutics has a value for money and ROI score of 3.3 out of 5 stars rated by its users and customers.
Sign Up to unlock Intellia Therapeutics' overall ROI score rated by its users and customers.
Compared to its competitors, Intellia Therapeutics's ROI score is rated right above Alnylam Pharmaceuticals, and is preceded by Biogen.
| COMPANY | Pricing Score | |
|---|---|---|
![]() | Spark Therapeutics | 5/5 |
![]() | Caribou Biosciences | 5/5 |
![]() | Agios Pharmaceuticals | 5/5 |
![]() | Vertex Pharmaceuticals | 4/5 |
![]() | bluebird bio | 4/5 |
![]() | Illumina | 3.9/5 |
![]() | Biogen | 3.8/5 |
![]() | Intellia Therapeutics | 3.3/5 |
![]() | Alnylam Pharmaceuticals | 3/5 |
![]() | Editas Medicine | N/A |
![]() | Rubius Therapeutics | N/A |
Intellia Therapeutics has an overall Customer Satisfaction score of 60 rated by its users and customers.
Sign Up to see the full customer demographics data and the people that answered "How would you rate your overall satisfaction with the service you received?"
Customer Satisfaction Score (also known as CSAT), is a metric used to quantify how satisfied customers are with a company or brand’s products and services. The Customer Satisfaction Score is based on customers response to the question: “How would you rate your overall satisfaction with the service you received?” The score is calculated using the formula: (The total number answer of “Very Satisfied” and “Satisfied”) ÷ (The total response) x100, and it is generally displayed in percentages. Some of the main benefits of the CSAT for businesses are tracking retention, identifying happy customers and growing relationships, and gaining repeat business to build a sustainable brand.
Compared to its competitors, Intellia Therapeutics's Customer Satisfaction score is rated right above Spark Therapeutics, and is preceded by Alnylam Pharmaceuticals.
| COMPANY | Customer Satisfaction (CSAT) Score | |
|---|---|---|
![]() | Caribou Biosciences | 100% |
![]() | bluebird bio | 83% |
![]() | Biogen | 78% |
![]() | Illumina | 72% |
![]() | Vertex Pharmaceuticals | 68% |
![]() | Alnylam Pharmaceuticals | 67% |
![]() | Intellia Therapeutics | 60% |
![]() | Spark Therapeutics | 50% |
![]() | Agios Pharmaceuticals | 50% |
![]() | Editas Medicine | 0% |
![]() | Rubius Therapeutics | 0% |
Intellia Therapeutics has an overall Customer Service score of 3.9 out of 5 stars rated by its users and customers.
Sign Up to unlock Intellia Therapeutics' overall Customer Service score rated by its users and customers.
40 Erie Street, Cambridge, MA 02139
http://www.intelliatx.com
857-285-6200
Compared to its competitors, Intellia Therapeutics's Customer Service score is rated right above Biogen, and is preceded by bluebird bio.
| COMPANY | Customer Service Score | |
|---|---|---|
![]() | Spark Therapeutics | 5/5 |
![]() | Caribou Biosciences | 5/5 |
![]() | Vertex Pharmaceuticals | 3.9/5 |
![]() | Illumina | 3.9/5 |
![]() | bluebird bio | 3.9/5 |
![]() | Intellia Therapeutics | 3.9/5 |
![]() | Biogen | 3.8/5 |
![]() | Alnylam Pharmaceuticals | 3.3/5 |
![]() | Agios Pharmaceuticals | 2.5/5 |
![]() | Editas Medicine | N/A |
![]() | Rubius Therapeutics | N/A |
Intellia Therapeutics has a 4.2/5 stars for its overall company culture rated by their employees

Intellia Therapeutics scored a 49 for Net Promoter Score and a 30 for Employee Net Promoter Score. NPS gauges how likely a customer of Intellia Therapeutics would recommend the brand to a friend. ENPS measures how likely Intellia Therapeutics employees would recommend working at Intellia Therapeutics to a friend.
| 66% | Promoters |
|---|---|
| 17% | Passive |
| 17% | Detractors |
| 60% | Promoters |
|---|---|
| 10% | Passive |
| 30% | Detractors |